$TRAW
Traws Pharma, Inc. Common Stock
XNAS
Why is TRAW down today? It is at $0.541 (-2.33%). See the catalyst behind the move, real-time alerts the moment TRAW spikes, and full due diligence on TRAW — key stats, earnings, dilution and insider activity. Free.
Get free $TRAW alerts the moment volume spikes
Be first to know when $TRAW makes an unusual move. Create a free account to track $TRAW, build a watchlist, and get instant unusual-volume alerts — plus 5 free premium days, no card needed.
No card · 5 premium days · join 800+ traders
Key Stats
- Price
- $0.541
- Change today
- -2.33%
- Previous close
- $0.554
- 52-week range
- $0.430 – $3.27
- Market cap
- $8M
- Total held
- 8.0%
- Tradeable float
- 13.9M 92% of shares · after 8% insiders + institutional n/a
- Short interest
- 700K ▼ -29% vs prior · as of 2026-07-15
- Short % of float
- 5.0%
- Days to cover
- 3.8d
- Avg daily volume
- 772K
- Next earnings
- Aug 13 · in 7d
- Exchange
- XNAS
- 5m
- 2.2x
- 15m
- 2.2x
- 1h
- 2.0x
- 1D
- 0.1x
Get free TRAW + market alerts in your inbox
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Why is $TRAW down today?
Here is the latest on TRAW from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for TRAW today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
Likely catalystListing deficiency / delisting risk, from the latest SEC filing. Read it →Analyst data via Nasdaq. Not investment advice.
Insiders
1 open-market buy0 buys, 0 sells last 3 months (11/0 over 12 months)Show 12 recent transactionsMinimize 12 recent transactions
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Orbimed Advisors Llc Beneficial Owner (10%) | Bought (open market) | +598K 3.9% of company | added 99% | 1.20M | $998K at $1.67 | Apr 16, 26 |
Savchuk Nikolay Officer | Acquired (grant/award) | +16K 0.1% of company | added 12% | 151K | n/a | Dec 12, 25 |
Redfield Robert Officer | Acquired (grant/award) | +16K 0.1% of company | added 17% | 114K | n/a | Dec 12, 25 |
Pauza Charles David Officer | Acquired (grant/award) | +18K 0.1% of company | added 19% | 116K | n/a | Dec 12, 25 |
Dukes Iain D. Officer | Acquired (grant/award) | +37K 0.2% of company | added 28% | 171K | n/a | Dec 12, 25 |
Stover Jack E Director | Acquired (grant/award) | +6K 0.04% of company | added 100% | 6K | n/a | Dec 12, 25 |
Shoemaker Mary Teresa Director | Acquired (grant/award) | +6K 0.04% of company | added 100% | 6K | n/a | Dec 12, 25 |
Cautreels Werner Director | Acquired (grant/award) | +5K 0.03% of company | added 4.7% | 109K | n/a | Dec 12, 25 |
Clarke Trafford Director | Acquired (grant/award) | +6K 0.04% of company | n/a | 6K | n/a | Dec 12, 25 |
Leaman John Harold Director | Acquired (grant/award) | +4K 0.03% of company | n/a | 4K | n/a | Dec 12, 25 |
Parker Charles Nolan Officer | Acquired (grant/award) | +15K 0.1% of company | n/a | 15K | n/a | Dec 12, 25 |
Tpav, Llc Beneficial Owner (10%) | Sold (automatic/other) | -606K 4.0% of company | n/a | n/a | n/a | Apr 2, 25 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Dilution watch
Active shelfAt-the-market (ATM) offering active — the company can keep selling new shares into the market over time (ongoing). If $TRAW runs, these filings show who may be positioned to sell new or newly-registered shares into the move.
- At-the-market (ATM) program — sells new shares into the market gradually over time · About $6M in size
Sourced from SEC EDGAR filings (last 9 months); terms read straight from the filing text where available. Ongoing = an at-the-market (ATM) program still selling over time or a live shelf, so it can keep diluting; Completed = a one-time priced sale that already finished. A shelf (S-3) stays effective ~3 years. Form type signals dilution capacity, not an exact share count, and we can't confirm how much of a shelf or ATM remains unused. Not investment advice.
$TRAW Sentiment
NeutralBlend of news sentiment, today’s move, and community votes. Not investment advice.
$TRAW Activity
News, unusual-volume alerts, AI-trader trades and community chatter — the whole story, newest first.
TRAW stock FAQ
Why is $TRAW down today?
Here is the latest on TRAW from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for TRAW today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
What is the TRAW stock price today?
TRAW last traded at $0.541, down 2.33% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
When does TRAW report earnings?
Traws Pharma, Inc. Common Stock (TRAW) is next expected to report earnings on Thursday, August 13, 2026, about 7 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
Where can I see live TRAW alerts?
The TRAW Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged TRAW 0 times in the last 30 days.
What exchange is TRAW on?
TRAW (Traws Pharma, Inc. Common Stock) trades on XNAS, with a market cap of about $8M.
Is TRAW good for day trading?
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge TRAW for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.